Specific binding molecules for fibroblast activation protein (FAP)
FAP-binding Affilin® proteins offer targeted diagnostic and therapeutic solutions for FAP-expressing cancers, addressing the limitations of current strategies and improving patient outcomes.
Patent Information
- Application Number
- JP2024531247
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-02-11
- Filing Date
- 2022-11-29
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2042-11-29
AI Technical Summary
Current diagnostic and treatment strategies for cancers with high fibroblast activation protein (FAP) expression are inadequate, leading to poor patient outcomes and limited therapeutic options.
Development of FAP-binding ubiquitin-derived molecules, known as Affilin® proteins, with high specificity and stability for targeting FAP-expressing tumors, enabling diagnostic imaging and therapeutic interventions.
Provides targeted diagnostic and therapeutic options for FAP-related cancers with minimal toxicity to normal tissues, improving patient outcomes by enhancing diagnostic accuracy and treatment efficacy.
Smart Images

Figure 2024543910000001_ABST
Abstract
Description
[Technical field]
[0001] FIELD OF THEINVENTION The present invention relates to new ubiquitin-derived molecules that specifically bind to Fibroblast Activation Proteins (FAPs). The invention further relates to FAP-binding ubiquitin-derived molecule (Affilin®) proteins that further comprise a diagnostically or therapeutically active component. Further aspects of the invention cover such FAP-binding proteins for use in medicine, e.g. for use in the diagnosis (including imaging) or treatment of FAP-associated tumors. [Background technology]
[0002] 2. Background of the Invention Cancer-associated fibroblasts (CAFs) interact with cancer cells. Cancer cells induce cancer-associated fibroblast activation, and cancer-associated fibroblasts support tumor growth, metastasis, invasion, and immunosuppression. The protease expressed by activated CAFs is fibroblast activation protein (FAP; also known as prolyl endopeptidase FAP, dipeptidyl peptidase FAP, integral membrane serine protease, surface-expressed protease, etc.). FAPs, which are stromal cell surface proteases, thereby affect extracellular matrix remodeling, signal transduction, immunosuppression, and other processes.
[0003] FAP is highly upregulated in many cancers, including almost all carcinomas, such as breast, colorectal, pancreatic, lung, brain, intrahepatic bile duct, and ovarian cancer. Additionally, high levels of FAP expression can be detected in some tumors derived from non-epithelial tissues, such as melanoma and myeloma. Overexpression of FAP promotes tumorigenesis and metastasis. It is not expressed or is only weakly expressed on adult normal tissues. Examples are uterus, cervix, placenta, breast, and skin, which show low to moderate expression compared to tumors. However, high expression of FAP occurs in wound healing, inflammation, such as arthritis, atherosclerotic plaque, fibrosis, as well as in ischemic heart tissue after myocardial infarction.
[0004] The application of FAP in the diagnosis and treatment of various cancers has been reported. Some antibodies have been developed as ligands of FAP, such as sibrotuzumab. Sibrotuzumab failed in Phase II clinical trials for metastatic colorectal cancer despite its tumor stroma targeting properties. Additionally, 8 of 26 patients treated with sibrotuzumab developed human-anti-human antibodies with changes in pharmacokinetics, and tumor uptake was reduced in 4 of these patients. Therefore, further clinical development of sibrotuzumab was stopped.
[0005] High expression levels of FAP are associated with poor prognosis for patients. However, diagnosis and treatment of FAP-related cancers are not adequately addressed by existing options, and as a result, many patients do not fully benefit from current strategies.
[0006] Clearly, there is an urgent need for new strategies for the diagnosis and treatment of tumors with FAP overexpression. Summary of the Invention
[0007] One objective of the present invention is to provide molecules for specific targeting of FAP to enable targeted diagnosis and treatment options, including imaging of FAP-positive tumors, for example, by radiodiagnostic methods and FAP-targeting radiopharmaceuticals.Targeting this tumor-associated protein can benefit patients with unmet need for new diagnostic and therapeutic pathways.Specific targeting of FAP suggests a potentially non-toxic diagnostic and treatment approach due to the low and limited distribution of FAP in normal tissues.Therefore, binding proteins with specificity for FAP can enable effective medical options for cancer and ultimately improve the quality of life of patients.
[0008] The present invention provides novel FAP-binding molecules for new and improved strategies in the diagnosis and treatment of FAP-related cancers. Furthermore, the novel FAP-binding molecules of the present invention provide improved strategies in the diagnosis and treatment of cancers related to FAP overexpression.
[0009] The above objects and advantages are achieved by the subject matter of the appended claims. The present invention fulfills the above-stated needs by providing exemplary FAP binding proteins. The above summary does not necessarily describe all problems solved by the present invention.
[0010] Summary of the Invention The present disclosure provides the following items 1 to 11, but is not limited thereto:
[0011] 1. A protein comprising an amino acid sequence at least 80% identical to any one selected from the group of SEQ ID NOs: 1-12, 15-27, and having a specific binding affinity for human fibroblast activation protein (hFAP) of less than 100 nM. In some embodiments, a protein comprising an amino acid sequence at least 90% identical to any one selected from the group of SEQ ID NOs: 1-12, 15-27 has a specific binding affinity for hFAP of less than 50 nM.
[0012] 2. The protein of item 1, which is a multimer. The multimer contains a plurality of the proteins of item 1. The multimer is a dimer, trimer, or tetramer of the protein of item 1.
[0013] 3. The protein according to items 1 or 2, which is a fusion protein. The fusion protein contains the protein according to items 1 or 2.
[0014] 4. The protein of items 1-3, additionally comprising at least one linking site for linking a chemical moiety. Optionally, the chemical moiety is selected from any of a chelator, a drug, a toxin, a dye, and a small molecule.
[0015] 5. The protein according to any one of items 1 to 4, wherein the fusion protein additionally comprises at least one diagnostically active moiety. Optionally, the diagnostically active moiety is selected from a radionuclide, a fluorescent protein, a photosensitizer, a dye, an enzyme, a magnetic bead, a metal bead, a colloidal particle, an electron-dense reagent, biotin, digoxigenin, a hapten, CAR-T, or an exosome, or any combination thereof.
[0016] 6. The protein of items 1 to 4, additionally comprising at least one therapeutically active moiety. Optionally, the diagnostically active moiety is selected from a monoclonal antibody or fragment thereof, a binding protein, a receptor or receptor domain, a receptor ligand, a radionuclide, a cytotoxic compound, a cytokine, a chemokine, an enzyme, a CAR-T, or an exosome, or a derivative thereof, or any combination of the above.
[0017] 7. The protein of items 1-6, additionally comprising at least one pharmacokinetic modulating moiety. Optionally, the pharmacokinetic modulating moiety is selected from serum albumin, albumin binding protein, immunoglobulin binding protein, or immunoglobulin or immunoglobulin fragment, polysaccharide, unstructured amino acid sequence including the amino acids alanine, glycine, serine, proline, polyethylene glycol, sialic acid, or transferrin.
[0018] 8. The protein of items 1 to 7 for use in the diagnosis or treatment of a FAP-associated disease, such as a FAP-associated tumor.
[0019] 9. A composition comprising a protein according to items 1 to 8 for use in medicine, preferably for use in the diagnosis or treatment of a FAP-related disease.
[0020] 10. A method for producing a protein according to any one of items 1 to 8, comprising the steps of a) culturing a host cell under suitable conditions for obtaining said protein, and b) isolating the produced protein.
[0021] 11. A method for detecting a FAP constituting a sample using a protein according to any one of items 1 to 8, and for detecting binding of the FAP using a protein according to any one of items 1 to 8, comprising contacting a sample with the protein according to any one of items 1 to 8.
[0022] This summary does not necessarily describe all features of the invention: other embodiments will become apparent from consideration of the subsequent detailed description. [Brief description of the drawings]
[0023] [Figure 1]FIG. 1 shows the analysis of Affilin® protein binding to hFAP-Fc (label-free interaction assay using SPR). hFAP was immobilized on a CM-5 chip. KD values were calculated after fitting the data with a 1:1 Langmuir model. FIG. 1A shows Affilin®-217990 (SEQ ID NO: 1) to hFAP (KD=14 nM). FIG. 1B shows Affilin®-217832 (SEQ ID NO: 4) to hFAP (KD=3 nM). FIG. 1C shows Affilin®-217993 (SEQ ID NO: 11) to hFAP (KD=23 nM). [Diagram 2] Figure 2 shows the analysis of the binding of Affilin®-217990 with high affinity to mFAP-Fc (label-free interaction assay using SPR). mFAP was immobilized on a CM-5 chip. After fitting the data with a 1:1 Langmuir model, a KD value of 90 nM was calculated. [Diagram 3] Figures 3, 4, 5, and 6 show the binding affinity of the FAP-binding protein in serum after 24 hours of incubation. The KD values for hFAP-Fc were determined after 0 hours of serum incubation (filled circles) and after 24 hours of incubation at 37°C in serum (filled triangles) (KD determination by ELISA in Figures 3-5, KD determination by flow cytometry in Figure 6). After 24 hours of incubation in serum, the KD values showed only minor fluctuations compared to the KD values before incubation in serum, confirming the stability of the FAP-specific Affilin® protein. Figure 3 shows the binding affinity of the FAP-binding protein Affilin®-217990 (SEQ ID NO: 1) in human serum (Figure 3A) and mouse serum (Figure 3B). [Figure 4] FIG. 4 shows the binding affinity of the FAP-binding protein Affilin®-220257 (SEQ ID NO: 22) in human serum (FIG. 4A) and mouse serum (FIG. 4B). [Diagram 5]FIG. 5 shows the binding affinity of the FAP-binding protein Affilin®-220164 (SEQ ID NO: 19) in human serum (FIG. 5A) and mouse serum (FIG. 5B). [Figure 6] FIG. 6 shows the binding affinity of FAP-specific Affilin®-217863 (SEQ ID NO:5) in human serum. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0024] Detailed Description of the Invention The present inventors have developed a solution to meet the strong and current need in the art to expand medical options for cancer diagnosis and treatment by providing novel FAP-binding proteins. The FAP-specific proteins defined herein are functionally characterized by high specific affinity for FAP, even on cells expressing the FAP. Moreover, they exhibit a high level of stability in serum (i.e., characterized by binding affinity to FAP). The present invention provides FAP-binding proteins based on the ubiquitin scaffold (also known as Affilin® molecules). The FAP-binding proteins described herein thereby provide a molecular format with favorable physicochemical properties, high-level expression in bacteria, and allow for easy manufacturing methods. The novel FAP-binding proteins may open up previously unmet medical strategies for the diagnosis and therapy of FAP-associated cancers. In particular, the FAP-binding proteins may be used for imaging purposes, for example, for the presence of tumor cells expressing FAP, and for radiotherapy treatment of tumors expressing FAP, or for immuno-oncological treatment options.
[0025] Before the present invention is described in more detail below, it should be understood that the present invention is not limited to the specific methodology, protocols and reagents described herein, which may be modified. It should also be understood that the technical terms used herein are only for the purpose of describing specific aspects and embodiments, and are not intended to limit the scope of the present invention reflected by the appended claims. Unless otherwise defined, all scientific and technical terms used herein have the same meaning as commonly understood by those skilled in the art to which the present invention belongs. This includes those skilled in the art of protein engineering and purification, but also those skilled in the art of developing new target-specific binding molecules for technical applications and use in therapy and diagnosis.
[0026] Preferably, the terms used herein are defined as set forth in "A multilingual glossary of biotechnological terms: (IUPAC Recommendations)", Leuenberger, HGW, Nagel, B. and Kolbl, H. eds. (1995), Helvetica Chimica Acta, CH-4010 Basel, Switzerland).
[0027] Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", as well as variations such as "comprises" and "comprising", are understood to imply the inclusion of a stated integer or step, or group of integers or steps, but not the exclusion of any other integer or step or group of integers or steps. The terms "comprise(s)" or "comprising" may include the limitation to "consists of" or "consisting of", if such a limitation is necessary for any reason and to any extent.
[0028] Several documents (e.g., patents, patent applications, scientific publications, manufacturer's specifications, instructions, UniProt accession numbers, etc.) may be referenced throughout this specification. Nothing herein should be construed as an admission that the present invention is not entitled to antedate such disclosure by virtue of prior invention. Some of the documents referenced herein may be characterized as "incorporated by reference." In the event of a conflict between the definitions or teachings of such incorporated references and those set forth herein, the description of this specification shall prevail.
[0029] All sequences referred to herein are disclosed in the attached sequence listing (WIPO ST.26 *.xml format), which together with its entire content and disclosure forms part of the disclosure content of the present specification. For the avoidance of doubt and as a precautionary measure, the sequence listing according to WIPO ST.25, which forms part of the priority application EP 22 156 353.9, is incorporated herein by reference.
[0030] General definitions of important terms used in this application The term "FAP" as used herein refers to Uniprot accession number Q12884. It refers to fibroblast activation protein (FAP), also known as prolyl endopeptidase FAP, dipeptidyl peptidase FAP, integral membrane serine protease, surface-expressed protease, etc. The term "FAP" includes all polypeptides that exhibit at least 70%, 75%, 80%, 85%, 90%, 95%, 96% or 97% or more, or 100% sequence identity to the FAP of Uniprot accession number Q12884 (human). Human FAP is 89.5% identical to mouse FAP (accession number P97321), 88.6% identical to rat FAP, and 99.6% identical to cynomolgus monkey FAP (accession number A0A2K5VGF4). The term "FAP" includes the extracellular domain of FAP (residues 26-760).
[0031] The terms "FAP binding protein" or "FAP-specific Affilin® protein" or "protein comprising a FAP binding protein" are used interchangeably herein and refer to a protein with high affinity binding to a FAP.
[0032] The term "Affilin®" is a registered trademark of Navigo Proteins® GmbH and refers to non-immunoglobulin derived binding proteins. In the context of the present invention, the term "Affilin" refers to ubiquitin muteins.
[0033] The terms "protein" and "polypeptide" refer to any chain of two or more amino acids linked by peptide bonds and do not refer to a specific length of the product. Thus, "peptide", "protein", "amino acid chain", or any other term used to refer to a chain of two or more amino acids, are included within the definition of "polypeptide", and the term "polypeptide" may be used in place of or interchangeably with any of these terms. The term "polypeptide" is also intended to refer to products of post-translational modifications of polypeptides, which are well known in the art.
[0034] The term "modification" or "amino acid modification" refers to the replacement, deletion, or insertion of a reference amino acid at a specific position in a parent polypeptide sequence with another amino acid. Considering the known genetic code and recombinant and synthetic DNA techniques, a person skilled in the art can easily construct DNA encoding amino acid variants.
[0035] The term "ubiquitin" refers to the amino acid sequence given in SEQ ID NO: 13 and proteins having at least 95% identity, such as those with point mutations at positions 45, 75, 76 that do not affect binding to FAP.
[0036] The term "mutein" as used herein refers to a derivative of ubiquitin, e.g., as shown in SEQ ID NO: 13, which differs from said amino acid sequence by amino acid exchange, insertion, deletion, or any combination thereof, but has specific binding affinity to FAP. The FAP-binding protein of the present invention is a ubiquitin mutein protein (ubiquitin mutein). The term "substitution" is understood as the replacement of an amino acid by another amino acid. The term "insertion" includes the addition of an amino acid to the original amino acid sequence.
[0037] The terms "binding affinity" and "binding activity" may be used interchangeably herein and refer to the ability of a polypeptide to bind to another protein, peptide, or fragment or domain thereof. Binding affinity is measured by the equilibrium dissociation constant (K), which is used to assess and rank the order of strength of a bimolecular interaction. D ) is typically measured and reported by
[0038] The term "fusion protein" refers to a protein that comprises at least a first protein genetically connected to at least a second protein. Fusion protein is created through the connection of two or more genes that originally code for separate proteins. Fusion protein may further comprise additional domains that are not involved in target binding, such as, but not limited to, a multimerization moiety, a polypeptide tag, a polypeptide linker, or a moiety that binds to a target different from FAP.
[0039] The term "amino acid sequence identity" refers to the quantitative comparison of the identity (or difference) of the amino acid sequences of two or more proteins. "Amino acid sequence identity percentage (%)" with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in the sequence that are identical to the amino acid residues in the reference polypeptide sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum sequence identity percentage. To determine sequence identity, the sequence of the query protein is aligned to the sequence of the reference protein or polypeptide. Methods of sequence alignment are well known in the art. For example, to determine the degree of amino acid sequence identity of any polypeptide compared to another amino acid sequence, the SIM local similarity program, as known in the art, is preferably used. For multiple alignment analysis, Clustal Omega is preferably used, as known to those skilled in the art.
[0040] As used herein, the phrases "percent identical" or "percent (%) amino acid sequence identity" or "percent identity," in the context of two polypeptide sequences, refer to two or more sequences or subsequences that, when compared and aligned for maximum correspondence as measured using one of the following sequence comparison algorithms or by visual inspection, have in some embodiments at least 80%, in some embodiments at least 85%, in some embodiments at least 90%, in some embodiments at least 91%, in some embodiments at least 92%, in some embodiments at least 93%, in some embodiments at least 94%, in some embodiments at least 95%, in some embodiments at least 96%, in some embodiments at least 97%, in some embodiments at least 98%, and in some embodiments 100% amino acid residue identity. For reasons of clarity, for example, a sequence having at least 80% identity includes all sequences having more than 80% identity, such as embodiments having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% amino acid identity. For reasons of clarity, for example, a sequence having at least 90% identity includes all sequences having 90% or more than 90% identity, such as embodiments having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% amino acid identity.
[0041] The term "fused" means that polypeptide components or units are linked by peptide bonds, either directly or via a peptide linker. In various embodiments, the term "fused" can mean that the polypeptide components or units are linked by a non-peptide linker, for example, through chemical conjugation.
[0042] The term "fusion protein" refers to a protein that comprises at least a first protein genetically connected to at least a second protein. Fusion proteins are created through the connection of two or more genes that originally encoded separate proteins. Thus, fusion proteins may comprise multimers of the same or different proteins expressed as a single linear polypeptide. In various embodiments, fusion proteins are created through the connection of two or more polypeptides via a non-peptide linker, for example, through chemical conjugation. Fusion proteins may further comprise additional domains that are not involved in target binding, such as, but not limited to, a multimerization moiety, a polypeptide tag, a polypeptide linker, or a moiety that binds to a target different from the FAP.
[0043] DETAILED DESCRIPTION OF EMBODIMENTS OF THE PRESENTINVENTION Structural characterization of FAP binding proteins. The FAP binding proteins described herein comprise, consist essentially of, or consist of an amino acid sequence selected from any one of the group: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, or the FAP binding proteins are selected from an amino acid sequence having at least 80% identity thereto, respectively. In various embodiments, the FAP binding protein comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 1-12, and 15-27, or an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto. In various embodiments, the FAP binding protein comprises, consists essentially of, or consists of an amino acid sequence of any of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to any of SEQ ID NOs: 1-12, and 15-27.
[0044] All FAP-binding proteins are ubiquitin-based and structurally related. All FAP-binding proteins described herein share the same basic protein scaffold.
[0045] In some embodiments, the modifications in ubiquitin that result in binding to a FAP are present in the region corresponding to amino acids 6-15, and / or 42-46, and / or 62-72 of ubiquitin (SEQ ID NO: 13).
[0046] In some embodiments, the FAP-specific ubiquitin mutein has an aromatic amino acid at position 64 of SEQ ID NO:13 (E64W or E64F).
[0047] In some embodiments, the FAP-specific ubiquitin mutein has a proline (P) at position 65 of SEQ ID NO:13 (S65P).
[0048] In some embodiments, the FAP-specific ubiquitin mutein has an aromatic amino acid at position 64 of SEQ ID NO: 13 (E64W or E64F) and a proline (P) at position 65 of SEQ ID NO: 13 (S65P). In some embodiments, the FAP-specific ubiquitin mutein has an aromatic amino acid at position 6 of SEQ ID NO: 13 (K6W or K6Y).
[0049] In some embodiments, the FAP-specific ubiquitin mutein has a basic amino acid at position 46 of SEQ ID NO:13 (A46K or A46R).
[0050] Some embodiments provide a FAP-specific ubiquitin mutein having at least seven additional substitutions at positions 6, 8, 9, 10, 12, 42, 44, 45, 46, 62, 63, 66, 68, and 70 of SEQ ID NO:13.
[0051] In some embodiments, one or more additional substitutions in the ubiquitin moiety are provided.
[0052] In some embodiments, the FAP-specific ubiquitin mutein has an additional insertion of six amino acids between the positions corresponding to positions 9 and 10 (see, e.g., SEQ ID NOs: 1, 2, 15, 16; Affilin®-217990, Affilin®-217966, Affilin®-219750, Affilin®-220198, respectively). In some embodiments, the FAP-specific ubiquitin mutein has an additional insertion of six amino acids between the positions corresponding to positions 9 and 10 of SEQ ID NO: 13 (ubiquitin): (i) an alanine (A) at the amino acid position corresponding to position 44 of SEQ ID NO: 13 (exchange I44A; corresponding to position 50 in the Affilin® proteins of SEQ ID NOs: 1, 2, 15, 16), and / or (ii) a glycine (G) at the amino acid position corresponding to position 64 of SEQ ID NO: 13 (exchange E64G; corresponding to position 70 in the Affilin® proteins of SEQ ID NOs: 1, 2, 15, 16), and / or (iii) a lysine (K) at the amino acid position corresponding to position 70 of SEQ ID NO: 13 (exchange V70K; corresponding to position 76 in the Affilin® proteins of SEQ ID NOs: 1, 2, 15, 16) has.
[0053] In some embodiments, one or more additional substitutions in the ubiquitin moiety are provided.
[0054] In various embodiments, the FAP binding protein comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 1, or amino acids having at least 80% identity, at least 85% identity, or at least 90% identity to SEQ ID NO: 1. For example, SEQ ID NO: 1 (217990) is 93.9% identical to SEQ ID NO: 2 (217996) and SEQ ID NO: 16 (220198), respectively. SEQ ID NO: 1 (217990) is 87.8% identical to SEQ ID NO: 15 (217750).
[0055] In various embodiments, the FAP binding protein comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO:4, or an amino acid sequence having at least 80% identity, at least 85% identity, or at least 90% identity to SEQ ID NO:4.
[0056] In various embodiments, the FAP binding protein comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO:19, or an amino acid sequence having at least 80% identity, at least 85% identity, or at least 90% identity to SEQ ID NO:19.
[0057] Functional characterization The FAP binding proteins described herein have a binding affinity (K D ). In some embodiments, the FAP binding proteins described herein bind to human FAP with a measurable binding affinity of less than 100 nM, less than 50 nM, less than 25 nM, less than 15 nM, or even less than 10 nM. Suitable methods are known to those skilled in the art or described in the literature. Methods for determining binding affinity are known per se and can be selected, for example, from the following methods known in the art: enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR), kinetic exclusion analysis (KinExA assay), biolayer interferometry (BLI), flow cytometry, fluorescence spectroscopy, isothermal titration calorimetry (ITC), analytical ultracentrifugation, radioimmunoassay (RIA or IRMA), and enhanced chemiluminescence (ECL). Some of the methods are described in the following examples. In some embodiments, the FAP binding proteins described herein bind to human FAP with a measurable binding affinity of less than 100 nM, less than 50 nM, less than 25 nM, less than 15 nM, or even less than 10 nM, as determined by surface plasmon resonance. Typically, the dissociation constant K D is determined at 20°C, 25°C, or 30°C. DThe lower the value, the higher the binding affinity of the biomolecule for its binding partner. D The higher the value, the weaker the binding partners bind to each other (see figures and examples). In one embodiment, the FAP binding protein has a dissociation constant K for human FAP in the range of 0.1 nM to 100 nM, preferably 0.1 nM to 50 nM, more preferably 0.1 nM to 25 nM, and even more preferably 0.1 nM to 15 nM. D In some embodiments, the FAP binding proteins of the invention bind to human FAP and cynomolgus monkey FAP. In some embodiments, the FAP binding proteins of the invention bind to human FAP and mouse FAP.
[0058] A preferred embodiment relates to a protein comprising an amino acid sequence that is at least 90%, preferably at least 94% or at least 95%, identical to any one selected from the group consisting of SEQ ID NOs: 1-12, 15-27, and having a specific binding affinity for human fibroblast activation protein (hFAP) of less than 50 nM.
[0059] Other preferred embodiments relate to proteins comprising an amino acid sequence with at least 90%, preferably at least 94% or at least 95% identity to any one selected from the group of SEQ ID NOs: 1-12, 15-27, and having a specific binding affinity for human fibroblast activation protein (hFAP) of less than 25 nM. Some preferred embodiments relate to proteins comprising an amino acid sequence with at least 90%, preferably at least 94% or at least 95% identity to any one selected from the group of SEQ ID NOs: 1-12, 15-27, and having a specific binding affinity for human fibroblast activation protein (hFAP) of less than 15 nM. Some preferred embodiments relate to proteins comprising an amino acid sequence with at least 90%, preferably at least 94% or at least 95% identity to any one selected from the group of SEQ ID NOs: 1-12, 15-27, and having a specific binding affinity for human fibroblast activation protein (hFAP) of less than 10 nM.
[0060] In some embodiments, the FAP binding proteins described herein are particularly stable under different conditions, as shown in the Examples and Figures.
[0061] In some embodiments, the FAP binding protein is stable in the presence of serum at 37° C. for at least 24 hours. In some embodiments, as described in more detail in the Examples, the FAP binding protein is stable in the presence of human serum at 37° C. for at least 24 hours. In some embodiments, the FAP binding protein is stable in the presence of mouse serum at 37° C. for at least 24 hours. For example, the stability of the FAP binding protein can be measured by measuring the binding affinity (K ) after incubation in serum for extended periods of time (e.g., 24 hours) at temperatures as high as 37° C. using standard methods described herein above and in the Examples and Figures. D) can be determined. Binding affinity for FAP can be assessed for each binding protein before and after serum incubation as described herein. Some preferred embodiments relate to proteins comprising an amino acid sequence of at least 90%, preferably at least 94% or at least 95%, identity to any one selected from the group of SEQ ID NOs: 1-12, 15-27, and having a specific binding affinity for hFAP of less than 5 nM, preferably less than 2 nM, as determined via ELISA as described herein. Some preferred embodiments relate to proteins comprising an amino acid sequence of at least 90%, preferably at least 94% or at least 95%, identity to any one selected from the group of SEQ ID NOs: 1-12, 15-27, and having a specific binding affinity for hFAP of less than 5 nM, preferably less than 2 nM, as determined via ELISA as described herein, after 24 hours of incubation at 37° C. in serum.
[0062] FAP binding proteins that are stable in serum over extended periods of time at 37° C. exhibit no significant loss in binding affinity for the FAP, reflecting the exceptional stability of the FAP binding proteins described herein. No significant loss means that the binding affinity is not reduced by more than about half compared to the value obtained before incubation in serum.
[0063] In some embodiments, the FAP binding proteins described herein are stable at elevated temperatures, preferably at least 60° C., more preferably at least 70° C. For stability analysis, spectroscopic or fluorescence-based methods coupled with, for example, chemical or physical unfolding are known to those skilled in the art. For example, the stability of a molecule can be measured using standard methods, such as the thermal melting (T), which is the number of degrees Celsius (° C.) at which half of the molecule is unfolded. m ) temperature. Typically, T m The higher the , the more stable the molecule.
[0064] In some embodiments, specific binding of the FAP-specific Affilin® proteins described herein is confirmed by cellular FAP binding assays using overexpressing cells (see Examples). Cellular FAP binding of FAP-specific Affilin® proteins can be determined by standard methods, including immunofluorescence microscopy and flow cytometry analysis.
[0065] Multimers Some embodiments relate to a protein comprising an amino acid sequence at least 90% identical to any one selected from the group of SEQ ID NOs: 1-12, 15-27, having a specific binding affinity for human fibroblast activation protein (hFAP) of less than 50 nM, and being a multimer. In some embodiments, the FAP binding protein is a multimer comprising a plurality of FAP binding proteins as defined herein, e.g., an amino acid sequence at least 90%, preferably at least 94% or at least 95%, identical to any one selected from the group of SEQ ID NOs: 1-12, 15-27, and the protein has a specific binding affinity for human fibroblast activation protein (hFAP) of less than 50 nM. The multimer may comprise two, three, four or more FAP binding proteins. In one embodiment, the FAP binding protein comprises two, three, four or more FAP binding proteins linked together, i.e., the FAP binding protein can be a dimer, trimer, tetramer, etc. The multimers of the present invention are generally fusion proteins produced artificially by recombinant DNA techniques well known to those skilled in the art.
[0066] The multimer may comprise two FAP binding domains, and the FAP binding domain preferably comprises or essentially consists of the amino acid sequence described above.In some embodiments, the multimer is a dimer.The present invention provides a dimer of the amino acid sequence of SEQ ID NO:11, 12, 22.
[0067] In some embodiments, two or more FAP binding proteins are directly linked. In some embodiments, two or more FAP binding proteins are linked by a peptide linker. In various embodiments, two or more FAP binding proteins are linked via a peptide linker of up to 30 amino acids. In some embodiments, two FAP binding proteins are directly linked. In some embodiments, two FAP binding proteins are linked by a peptide linker.
[0068] Fusion proteins Some embodiments relate to a protein comprising an amino acid sequence at least 90%, preferably at least 94% or at least 95%, identical to any one selected from the group of SEQ ID NOs: 1-12, 15-27, having a specific binding affinity for human fibroblast activation protein (hFAP) of less than 50 nM, and which is a fusion protein. Some embodiments relate to a protein comprising an amino acid sequence at least 90%, preferably at least 94% or at least 95%, identical to any one selected from the group of SEQ ID NOs: 1-12, 15-27, having a specific binding affinity for human fibroblast activation protein (hFAP) of less than 50 nM, and which is a multimer of such amino acids, and which is a fusion protein.
[0069] In some embodiments, the protein of the invention is a fusion protein composed of a FAP binding protein as defined herein and at least a second protein. In some embodiments, the protein of the invention is a fusion protein comprising an amino acid sequence of at least 90%, preferably at least 94% or at least 95%, identity to any one selected from the group of SEQ ID NOs: 1-12, 15-27, having a specific binding affinity for human fibroblast activation protein (hFAP) of less than 50 nM, and comprising at least a second protein. Thus, some embodiments encompass fusion proteins comprising one or more FAP binding proteins disclosed herein and one or more additional polypeptides.
[0070] Connection part In some embodiments, the protein of the present invention comprises an amino acid sequence having at least 90%, preferably at least 94% or at least 95%, identity to any one selected from the group of SEQ ID NOs: 1-12, 15-27, where the protein has a specific binding affinity for human fibroblast activation protein (hFAP) of less than 50 nM, or a fusion protein comprising such amino acid sequence, and / or a multimer comprising the above amino acid sequence, and further one or more linking sites for linking a chemical moiety. In some embodiments, a protein comprising a FAP binding protein described herein further comprises one or more linking sites for linking a chemical moiety. The linking site has the ability to react with other chemical groups to link the FAP binding protein to the chemical moiety. The defined number and defined positions of the linking sites allow for site-specific linking of a chemical moiety to the FAP binding protein described herein. Thus, multiple chemical moieties can be linked to the FAP binding protein, if required. The number of linking sites can be adjusted to the optimal number for a particular application by one skilled in the art to adjust the amount of chemical moiety accordingly. In selected embodiments, the linking sites may be selected from a group of one or more amino acids that may be labeled with a particular chemistry, e.g., one or more cysteine residues, one or more lysine residues, one or more tyrosine, one or more tryptophan, or one or more histidine residues. The FAP binding protein may comprise 1-20 linking sites, preferably 1-6 linking sites, preferably 2 linking sites, or preferably 1 linking site.
[0071] Linked Domain One embodiment provides a FAP binding protein comprising at least one linking domain of 1-80 amino acids comprising one or more linking sites. In some embodiments, the linking domain of 1-80 amino acids may comprise alanine, proline, or serine, and a cysteine as the linking site. In other embodiments, the linking domain of 5-80 amino acids may consist of alanine, proline, serine, and a cysteine as the linking site. In one embodiment, the linking domain consists of 20-60% alanine, 20-40% proline, 10-60% serine, and one or more cysteines as the linking site at the C- or N-terminus of the FAP binding protein described herein. In some embodiments, the amino acids alanine, proline, and serine are randomly distributed throughout the linking domain amino acid sequence, such that no more than 2, 3, 4, or 5, preferably no more than 3 amino acids, are flanked by identical amino acid residues. The composition of the 1-20 linking domains can be different or identical.
[0072] In some embodiments, the chemical moiety is selected from any of chelators, drugs, toxins, dyes, and small molecules.In some embodiments, at least one of the chemical moieties is a chelator designed as a complexing agent for linking one or more additional moieties to targeted compounds to the FAP binding protein disclosed herein.One embodiment relates to the FAP binding protein in which the chelator is a complexing agent for linking one or more radioisotopes or other detectable labels.
[0073] Diagnostic part Various embodiments relate to a fusion protein comprising a FAP binding protein as described herein or a FAP binding protein as described herein and a diagnostic moiety. Various embodiments relate to a FAP binding protein as described herein and at least one diagnostic moiety. Various embodiments relate to a FAP binding protein as described herein and a diagnostic moiety. Various embodiments relate to a fusion protein comprising a FAP binding protein as described herein and a diagnostic moiety (i.e., at least one diagnostic moiety).
[0074] In some embodiments, such diagnostic moieties may be selected from radionuclides, fluorescent proteins, photosensitizers, dyes, enzymes, magnetic beads, metallic beads, colloidal particles, electron-dense reagents, biotin, digoxigenin, haptens, or any combination of those described above.
[0075] In some embodiments, the FAP binding proteins described above (including fusion proteins described herein) can be used, for example, as imaging agents, for example, to assess the presence of tumor cells or metastases, tumor distribution, and / or tumor recurrence. The method of detecting or monitoring cancer cells involves an imaging method. Such a method of imaging cancer cells includes proteins including the FAP binding proteins described herein (including fusion proteins described herein) conjugated to diagnostic moieties for imaging FAP-associated cancer cells, for example, by radioimaging or photoluminescence or fluorescence. In some embodiments, the method of imaging (detecting) cancer cells includes the FAP binding proteins described herein (including fusion proteins described herein) conjugated or linked to diagnostic moieties, for example, radionuclides or fluorescent proteins, for imaging FAP-associated tumor cells.
[0076] therapeutic part Various embodiments relate to a fusion protein comprising a FAP binding protein as described herein or a FAP binding protein as described herein and a therapeutic moiety. Various embodiments relate to a FAP binding protein as described herein and at least one therapeutic moiety. Various embodiments relate to a FAP binding protein as described herein and a therapeutic moiety. Various embodiments relate to a fusion protein comprising a FAP binding protein as described herein and a therapeutic moiety (i.e., at least one therapeutic moiety).
[0077] In some embodiments, such therapeutically active moieties may be selected from a monoclonal antibody or a fragment thereof, an extracellular domain of a receptor or a fragment thereof, a binding protein, a radionuclide, a cytotoxic compound, a cytokine, a chemokine, an enzyme, a CAR-T, or an exosome, or a derivative thereof, or any combination of the above.
[0078] In some embodiments, the FAP binding protein described herein or the fusion protein described herein that comprises a therapeutic active component is used in a method for targeted delivery of any of the components listed above to FAP-expressing tumor cells.Thereby, the FAP-specific binding protein accumulates in FAP-expressing tumor cells, and as a result of its high specificity for tumor cells, only low levels of toxicity to normal cells are expected.In some embodiments, the FAP binding protein described herein (including fusion protein) is conjugated or linked or connected to a therapeutic moiety described herein.
[0079] Radionuclides Suitable radionuclides for application in imaging (e.g., in vitro) or for treatment methods involving radiotherapy include, but are not limited to, for example, the group of gamma-emitting isotopes, the group of positron emitters, the group of beta emitters, and the group of alpha emitters.In some embodiments, suitable conjugation partners include chelators, such as 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) or diethylenetriaminepentaacetic acid (DTPA) or their activated derivatives, nanoparticles and liposomes.In various embodiments, DOTA can be suitable as a complexing agent for radioisotopes and other agents for imaging.
[0080] Pharmacokinetic-modulating moieties Various embodiments relate to a fusion protein comprising a FAP binding protein as described herein or a FAP binding protein as described herein and a pharmacokinetic modulating moiety. Various embodiments relate to a FAP binding protein as described herein and at least one pharmacokinetic modulating moiety. Various embodiments relate to a FAP binding protein as described herein and a pharmacokinetic modulating moiety. Various embodiments relate to a fusion protein comprising a FAP binding protein as described herein and a pharmacokinetic modulating moiety (i.e. at least one pharmacokinetic modulating moiety).
[0081] In some embodiments, the FAP binding proteins described herein or fusion proteins comprising the FAP binding proteins of the invention further comprise at least one pharmacokinetic modulating moiety, the pharmacokinetic modulating moiety being selected from albumin binding peptides, albumin binding proteins, polyethylene glycol, serum albumin (e.g. mouse serum albumin or human serum albumin), immunoglobulin binding peptides, immunoglobulins, immunoglobulin fragments, sialic acid, or transferrin, polysaccharides (e.g. hydroxyethyl starch), or unstructured amino acid sequences that increase hydrodynamic radius (e.g. multimers comprising the amino acids alanine, glycine, serine, proline). In some embodiments, the FAP binding proteins described herein or fusion proteins comprising the FAP binding proteins described herein are conjugated or linked or fused to the pharmacokinetic modulating moiety described above.
[0082] Some embodiments include fusion proteins comprising the FAP binding proteins described herein and a pharmacokinetic modulating moiety as described above.Some embodiments include fusion proteins comprising the FAP binding proteins described herein and an albumin binding peptide or albumin binding protein, an immunoglobulin binding peptide, or an immunoglobulin or immunoglobulin fragment.
[0083] In some embodiments, the FAP binding proteins described herein or fusion proteins comprising the FAP binding proteins are conjugated or linked or fused to a diagnostic moiety and further conjugated or linked or connected to a pharmacokinetic modulating moiety as described above. Some specific embodiments include a FAP binding protein described herein or a fusion protein comprising a FAP binding protein described herein and a radionuclide and a pharmacokinetic modulating moiety.
[0084] In some embodiments, the FAP binding protein or fusion protein comprising the FAP binding protein described herein is conjugated or linked or fused to a therapeutic moiety and further conjugated or linked or connected to a pharmacokinetic modulating moiety as described above.Some embodiments include a fusion protein comprising the FAP binding protein described herein or the FAP binding protein described herein and additionally a pharmacokinetic modulating moiety and a therapeutic moiety as described above.Some particular embodiments include a fusion protein comprising the FAP binding protein described herein or the FAP binding protein described herein and a therapeutic moiety and a pharmacokinetic modulating moiety as described above.
[0085] Several techniques are known in the art for producing proteins, including the FAP binding proteins described herein or fusion proteins containing FAP binding proteins, with extended half-life, such as direct fusion or chemical linkage (chemical coupling) of a pharmacokinetic modulating moiety to the FAP binding proteins described herein or fusion proteins containing FAP binding proteins described above. The pharmacokinetic modulating moiety can be attached, for example, at one or several sites of the FAP binding proteins described herein or fusion proteins containing FAP binding proteins through a peptide linker sequence or through the linkage sites described above.
[0086] Further parts In some embodiments, the conjugation of proteinaceous or non-proteinaceous moieties to the FAP binding proteins or fusion proteins comprising the FAP binding proteins described herein may be carried out by applying chemical methods well known in the art. In some embodiments, coupling chemistry specific to the derivatization of cysteine or lysine residues may be applicable. Chemical linkage (chemical coupling) may be carried out by chemistry well known to those skilled in the art, including but not limited to substitution, addition or cycloaddition, or oxidation chemistry (e.g., disulfide formation).
[0087] Purification / detection molecules In some embodiments, additional amino acids can be extended at either or both of the N-terminus or C-terminus of the FAP binding protein or fusion protein comprising the FAP binding protein described herein. Additional sequences can include, for example, sequences introduced for purification or detection. In one embodiment, additional amino acid sequences include one or more peptide sequences that confer affinity to certain chromatographic column materials. Typical examples for such sequences include, but are not limited to, Strep-tag, oligohistidine-tag, glutathione S-transferase, maltose binding protein, intein, intein fragment, or albumin binding domain of protein G.
[0088] FAP-BINDING PROTEINS FOR USE IN MEDICINE - Patent application Various embodiments relate to the FAP binding protein described herein or the fusion protein comprising the FAP binding protein disclosed herein for use in medicine. In one embodiment, the FAP binding protein described herein or the fusion protein comprising the FAP binding protein is used in medicine for diagnosing or treating cancer associated with FAP expression. The FAP binding protein described herein or the fusion protein comprising the FAP binding protein disclosed herein allows selective diagnosis and treatment of FAP-associated cancer cells or cancer tissues, for example, from breast, colorectal, pancreatic, lung, brain, intrahepatic bile duct, and ovarian cancer, or tumors derived from non-epithelial tissues, such as melanoma and myeloma. FAP binding protein is used in diagnosis (imaging) and treatment for most epithelial cancers, including breast, lung, colorectal, and pancreatic cancer. It is known that FAP is upregulated in tumor cells, which may result in uncontrolled proliferation of tumor cells and formation of metastases. In one embodiment, the FAP binding protein is used to diagnose FAP-associated tumors by applying in vitro methods.
[0089] One embodiment is a method of diagnosing (including monitoring) a subject with a FAP-associated tumor, the diagnostic (including monitoring / imaging) method comprising administering to the subject a FAP binding protein described herein or a fusion protein comprising the FAP binding protein described herein, optionally conjugated to a radioactive molecule. In various embodiments, the FAP binding protein described herein or a fusion protein comprising the FAP binding protein disclosed herein may be used in a method of diagnosing a FAP-associated tumor, optionally the FAP binding protein described herein or the fusion protein comprising the FAP binding protein is conjugated to a radioactive molecule. In some embodiments, the method of imaging a specific tissue or cell expressing a FAP comprises a FAP binding protein described herein or a fusion protein comprising the FAP binding protein described herein. In some embodiments, the method of imaging a specific tissue or cell expressing a FAP comprises a label conjugated to the FAP binding protein. In some embodiments, such a label is selected from a radioactive or fluorescent molecule. In some embodiments, the method of imaging a particular tissue or cell expressing a FAP comprises a label conjugated to a FAP binding protein that is used to visualize the FAP on the particular tissue or cell to assess, for example, the presence of FAP-associated tumor cells, FAP-associated tumor distribution, recurrence of FAP-associated tumors, and / or assess the patient's response to a therapeutic treatment. In some embodiments, the method is an in vitro method.
[0090] One embodiment is a method of treating a subject with FAP-associated cancer, the treatment method comprises administering to the subject the described FAP-specific binding protein, optionally conjugated to a radioactive molecule and / or a cytotoxic agent, or as a cancer immunotherapy. In various embodiments, the FAP-binding protein disclosed herein may be used in a method of treating FAP-associated cancer, optionally the FAP-binding protein is conjugated to a cytotoxic agent and / or a radioactive molecule, or expressed on the surface of target-specific cancer-associated fibroblasts (CAFs). For example, the cancer cells may be solid tumor cells. Some embodiments relate to the use of proteins, including FAP-binding proteins labeled with suitable radioisotopes or cytotoxic compounds, in a method of treating FAP-associated tumors, particularly to control or kill FAP-associated tumor cells, e.g., malignant cells. In one embodiment, a therapeutic dose of radiation is selectively delivered to FAP-associated tumor cells.
[0091] In some embodiments, the method of treating FAP-related disease comprises the FAP binding protein described herein or a fusion protein comprising the FAP binding protein disclosed herein.In some embodiments, the treatment of FAP-related disease comprises the FAP binding protein disclosed herein and an additional component for promoting immune response.As described herein, the FAP-related cancer can be any of breast cancer, colorectal cancer, pancreatic cancer, lung cancer, brain cancer, intrahepatic cholangiocarcinoma, epithelial cell carcinoma, squamous cell carcinoma, and ovarian cancer, or tumors derived from non-epithelial tissue, such as melanoma and myeloma.
[0092] composition Various embodiments relate to compositions comprising the FAP binding proteins described herein or fusion proteins comprising the FAP binding proteins disclosed herein. Compositions comprising proteins comprising the FAP binding proteins defined above for use in medicine, preferably for use in the diagnosis or treatment of FAP-related cancer. Compositions comprising the FAP binding proteins described herein or fusion proteins comprising the FAP binding proteins described above may be used in methods of diagnosis and / or treatment (including imaging) of FAP-related diseases. In particular, compositions comprising the FAP binding proteins described above may be used for methods of imaging, monitoring, and eliminating or inactivating pathological cells expressing FAP.
[0093] Various embodiments relate to diagnostic compositions for the diagnosis of FAP-associated cancers, comprising a FAP-binding protein as defined herein and a diagnostically acceptable carrier and / or diluent. These include, but are not limited to, stabilizers, surface active agents, salts, buffers, colorants, etc. The composition can be in the form of a liquid preparation, a lyophilisate, a granule, an emulsion or a liposomal preparation.
[0094] Diagnostic compositions comprising the FAP binding proteins described herein can be used for the diagnosis of the FAP-associated cancers described above.
[0095] Various embodiments relate to pharmaceutical (e.g., therapeutic) compositions for the treatment of diseases comprising the FAP binding proteins disclosed herein and pharma- ceutically (e.g., therapeutically) acceptable carriers and / or diluents. Pharmaceutical (e.g., therapeutic) compositions may optionally contain further auxiliary agents and excipients known per se. These include, but are not limited to, for example, stabilizers, surface active agents, salts, buffers, colorants, and the like. Therapeutic compositions may comprise the FAP binding proteins disclosed herein and further agents that promote immune responses (immuno-oncology agents). FAP-specific binding proteins disclosed herein as part of the composition may counteract the inhibition of immune responses.
[0096] Pharmaceutical compositions comprising a FAP binding protein as defined herein may be used for the treatment of the diseases mentioned above.
[0097] The composition contains an effective dose of FAP binding protein as defined herein.The amount of protein to be administered depends on the organism, the type of disease, the age and weight of the patient, and further factors known per se.Depending on the galenic preparation, these compositions can be administered parenterally by injection or infusion, systemically, intraperitoneally, intramuscularly, subcutaneously, transdermally, or by other conventionally used application methods.
[0098] The composition can be in the form of a liquid preparation, a lyophilisate, a cream, a lotion for external application, an aerosol form, a powder, a granular form, an emulsion or a liposomal preparation. The type of preparation depends on the type of disease, the route of administration, the severity of the disease, the patient and other factors known to those skilled in the medical art.
[0099] The various components of the composition may be packaged as a kit together with instructions for use.
[0100] Preparation of FAP-binding proteins The FAP binding proteins described herein may be prepared by any of a number of conventional and well-known techniques, such as conventional organic synthesis strategies, solid-phase assisted synthesis techniques, fragment ligation techniques, or commercially available automated synthesizers. On the other hand, they may also be prepared by conventional recombinant techniques, alone or in combination with conventional synthesis techniques. Furthermore, they may also be prepared by cell-free in vitro transcription / translation. Various embodiments relate to polynucleotides encoding the FAP binding proteins disclosed herein. One embodiment further provides an expression vector comprising said polynucleotide, and a host cell comprising said isolated polynucleotide or expression vector.
[0101] Various embodiments relate to methods of producing a FAP binding protein disclosed herein, comprising culturing a host cell under suitable conditions allowing expression of said FAP binding protein and optionally isolating said FAP binding protein.
[0102] For example, one or more polynucleotides encoding FAP-binding proteins may be expressed in a suitable host, and the produced FAP-binding proteins may be isolated. The host cell comprises said nucleic acid molecule or vector. Suitable host cells include prokaryotes or eukaryotes. Vector refers to any molecule or entity (e.g., nucleic acid, plasmid, bacteriophage or virus) that can be used to transfer protein-coding information into a host cell. Various cell culture systems, such as but not limited to mammalian, yeast, plant, or insect, can also be used to express recombinant proteins. Suitable conditions for culturing prokaryotic or eukaryotic host cells are well known to those skilled in the art. Cell culture and protein expression for the purpose of protein production can be performed at any scale, starting from small volume shaker flasks to large fermenters, applying techniques well known to those skilled in the art.
[0103] One embodiment is directed to a method for preparing a binding protein as detailed above, comprising the following steps: (a) preparing a nucleic acid encoding a FAP binding protein as defined herein; (b) introducing said nucleic acid into an expression vector; (c) introducing said expression vector into a host cell; (d) culturing the host cell; (e) subjecting the host cell to culture conditions in which the FAP binding protein is expressed, thereby producing a FAP binding protein as defined herein; (f) optionally isolating the FAP binding protein produced in step (e); and (g) optionally conjugating the FAP binding protein to a further functional moiety as defined herein.
[0104] In general, the isolation of purified FAP-binding proteins from the culture mixture can be carried out by applying conventional methods and techniques well known in the art, such as centrifugation, precipitation, flocculation, different embodiments of chromatography, filtration, dialysis, concentration and combinations thereof, and others. Chromatographic methods are well known in the art and include, but are not limited to, ion exchange chromatography, gel filtration chromatography (size exclusion chromatography), hydrophobic interaction chromatography or affinity chromatography.
[0105] For the simplification of purification, the FAP binding protein can be fused to other peptide sequences that have increased affinity for the separation material.Preferably, fusions are selected that do not have a detrimental effect on the functionality of the FAP binding protein or can be separated after purification due to the introduction of a specific protease cleavage site.Such methods are also known to those skilled in the art.
[0106] How to detect FAP Some embodiments relate to a method for detecting (human) FAP in a sample, comprising contacting the sample with the FAP binding protein of the present invention as described herein. In a preferred embodiment, the sample is obtained from a subject, and the subject is preferably a human subject. In a preferred embodiment, the sample is any one of, but not limited to, blood, plasma, serum, tissue, tissue fluid, and urine. In a preferred embodiment, the sample is or is obtained from cancer tissue or cancer biopsy, and the cancer is a FAP-associated cancer as described elsewhere herein. EXAMPLES
[0107] The following examples are provided for further illustration of the present invention. The present invention is particularly exemplified by the modification of ubiquitin resulting in its binding to FAP. The present invention is not, however, limited thereto, and the following examples are merely intended to demonstrate the feasibility of the present invention based on the above description.
[0108] Example 1: Mammalian Expression of Targets Expi293-F cells were cultured at 0.5-1 million cells / ml in Expi293-™ Expression medium (Fisher scientific, 13469756) in shake flasks at 135 rpm at 37°C, 8% CO2 and 95% humidity. One day before transfection, cells were seeded at a density of 2 million cells / ml. On the day of transfection, cells were seeded at a density of 2.5 million / ml. Plasmid DNA of hFAP-Fc, hCD26-Fc, mCD26-Fc, or 0.5 μg hFAP-AviHis and 0.5 μg hBirA per ml of culture volume for biotinylated hFAP-His, or 0.5 μg mFAP-AviHis and 0.5 μg hBirA per ml of culture volume for biotinylated mFAP-His, was used and diluted in Opti-MEM I Reduced Serum Medium (Life Technologies, 31985-062). ExpiFectamine (Thermo Fisher, A14524) was diluted in Opti-MEM I Reduced Serum Medium according to the manufacturer's information and incubated for 5 min at room temperature. Subsequently, the DNA solution was added to the ExpiFectamine mixture and incubated for 20 min at room temperature before it was added to the cells. For protein expression, the cells were incubated at 37°C, 8% CO2 and 95% humidity. Enhancer (Thermo Fisher, A14524) was added to the transfection mixture after 16 hours. Supernatants were collected after 96-120 hours, centrifuged, and filtered through a 0.45 μm membrane.
[0109] For production of mFAP-Fc, ExpiCHO cells were cultured at 500,000 cells / ml in ExpiCHO Expression Medium (Thermo Fisher Scientific, A2910001) (see above). Cells were seeded one day before transfection at a density of 4 million / ml. For transfection, cells were seeded at 6 million / ml. Plasmid DNA of mFAP-Fc was diluted in OptiPRO SFM (Thermo Fisher Scientific, 12309019) at 1 μg per ml of culture volume. ExpiFectamine (Thermo Fisher, A29129) was diluted in OptiPRO SFM and mixed with the DNA solution. After 3 min incubation at room temperature, the transfection mix was added to the cells. Cells were incubated for 24 h at 37°C. After 24 h incubation at 37°C, ExpiFectamine Enhancer and ExpiFectamine Feed were added and cells were incubated at 32°C. Supernatants were collected after 120 hours, centrifuged and filtered through a 0.45 μm membrane.
[0110] Example 2. Identification of FAP-binding proteins Library construction and library cloning Different proprietary libraries containing randomized amino acid positions in the ubiquitin and / or insert were synthesized in-house with randomized oligonucleotides generated by synthetic trinucleotide phosphoramidites (ELLA Biotech) to achieve a well-balanced amino acid distribution with simultaneous omission of cysteine and other amino acid residues at the randomized positions.
[0111] The corresponding cDNA library was amplified by PCR and ligated with a modified pCD87SA phagemid (referred to herein as pCD12) using standard methods known to those skilled in the art. The pCD12 phagemid contains a modified torA leader sequence (deletion of the amino acid sequence QPAMA) to achieve protein processing without additional amino acids at the N-terminus. An aliquot of the ligation mixture was used for electroporation of E. coli ER2738 (Lucigen). Established recombinant genetic methods were used unless otherwise indicated.
[0112] target Selections were performed using the extracellular domain of the human FAP protein and / or the extracellular domain of the mouse FAP protein as targets: on the one hand, an IgG1-Fc fusion protein was applied, and on the other hand, a biotinylated AviHis fusion protein was applied (cloned and expressed in-house as described in Example 1).
[0113] Primary selection by TAT phage display Phage display was used as a selection system to enrich the naive library for FAPs. After transformation of competent bacteria ER2738 cells (Lucigene) with the library-bearing phagemid pCD12, phage amplification and purification were performed using standard methods known to those skilled in the art. Target proteins were immobilized on magnetic beads for selection. Target proteins fused to IgG1-Fc were immobilized on Protein A Dynabeads. Site-specific biotinylated target proteins fused to AviHis tags were immobilized on M-270 Epoxy Dynabeads. The FAP concentration during phage incubation was reduced from 140 nM (first round) to 20 nM (third round) or 5 nM (fourth round) for biotinylated AviHis fusion target proteins containing target switches in each round between human and mouse FAPs, starting with human FAPs. The FAP concentration for the IgG1-Fc fusion target was reduced from 100 nM (1st round) to 20 nM (3rd round) or 5 nM (4th round) using only human FAPs.
[0114] Selection against IgG1-Fc fusion targets was performed in 3-4 rounds depending on the library and included pre-selection on gammanorm (Octopharma, Cat. No. PZN 13336380) on Protein A Dynabeads in round 2 and on the off-target extracellular domain of human CD26 (AcroBiosystems, Cat. No. DP4-H5266) fused to IgG1-Fc on Protein A Dynabeads in rounds 3 and 4. An additional pre-incubation of phage particles in mouse serum for 23 h at 37°C was performed before rounds 3 and 4.
[0115] Selection against biotinylated AviHis fusion targets was also performed in 3-4 rounds depending on the library, including preselection with only human CD26 fused to IgG1-Fc (AcroBiosystems, catalog no. DP4-H5266) on Protein A Dynabeads starting in round 3.
[0116] All selection rounds were performed using the automated KingFisher-System (Thermo Fisher) for isolation, washing and capture of the desired phage-target complexes on magnetic beads. FAP-bound phages were eluted with trypsin.
[0117] To identify target-specific phage pools, eluted and reamplified phages from each selection round were analyzed by phage pool ELISA. Wells of medium binding microtiter plates (Greiner Bio-One) were coated with human FAP (2.5 μg / ml) or mouse FAP (2.5 μg / ml), gammanorm (2.5 μg / ml), and human CD26 (2.5 μg / ml). Biotinylated AviHis-fused FAP was coated via streptavidin. Bound phages were detected using α-M13 HRP-conjugated antibody (GE Healthcare).
[0118] Cloning of target-binding phage pools into expression vectors The selected pools showing specific binding to the FAP in the phage pool ELISA were amplified by PCR according to methods known in the art, cut with the appropriate restriction nucleases and ligated into a derivative of the expression vector pET-28a (Merck, Germany) containing Strep-Tag II (IBA GmbH).
[0119] Single colony hit analysis After transformation of BL21(DE3) cells, kanamycin-resistant single colonies were picked automatically using a Qpix2 colony picker. Expression of FAP-binding proteins was achieved by culturing in 384-well plates (Greiner Bio-One) using auto induction medium (Studier, 2005, Protein Expr. Purif. 41(1):207-234). Cells were harvested and subsequently lysed mechanically by freeze / thaw cycles. After centrifugation, the resulting supernatants were first screened by ELISA with immobilized ProtA / FAP-Fc on a high binding 384 ELISA microtiter plate (Greiner Bio-One). Proteins bound to FAP-Fc were detected by Strep-Tactin HRP Conjugate (IBA GmbH) in combination with TMB-Plus substrate (Biotrend, Germany). The reaction was stopped by the addition of 0.2M H2SO4 solution and measured in a plate reader at 450 nm vs. 620 nm. In confirmation screening, binding of initial hits was analyzed against FAP-Fc (on-target) and IgG-Fc (off-target). Specific hits were selected for μ-scale purification, SPR analysis, sequencing, and further laboratory-scale expression and analysis.
[0120] Example 3A: Purification of target molecules Cell culture supernatants expressing hFAP-Fc-His, mFAP-Fc-His, hCD26-Fc-His, and mCD26-Fc-His were centrifuged and filtered for application to affinity chromatography on a HisTrap excel 1mL column or HiTrap Protein A HP 5ml (Cytiva, buffer conditions according to manufacturer's instructions). Cell culture supernatants expressing hFAP-Avi-His, mFAP-Avi-His, hCD26-Avi-His, and mCD26-Avi-His were centrifuged and filtered for application to affinity chromatography on a HisTrap excel 1mL column (Cytiva, buffer conditions according to manufacturer's instructions).
[0121] The eluted target protein was applied to a Superdex 200 XK 16 / 600 gel filtration column. The purity of the recovered target protein was analyzed and confirmed by SDS-PAGE and SE-HPLC. Enzyme activity was confirmed by fluorogenic assays based on the ability of the FAP target protein to convert the substrate benzyloxycarbonyl-Gly-Pro-7-amido-4-methylcoumarin (Z-GP-AMC) to 7-amino-4-methylcoumarin (AMC) and the ability of the CD26 off-target to convert H-Gly-Pro-7-amino-4-methylcoumarin (GP-AMC) to AMC.
[0122] Example 3B: Enzyme activity test of hFAP-Fc-His in the presence of Affilin® protein To determine whether Affilin® protein affects the enzymatic activity of hFAP-Fc-His, an activity assay was performed as described in Example 3A, but in the presence of Affilin® protein. Affilin®-217990 (SEQ ID NO: 1), Affilin®-217862 (SEQ ID NO: 3), Affilin®-217832 (SEQ ID NO: 4), Affilin®-217917 (SEQ ID NO: 6), Affilin®-217993 (SEQ ID NO: 11), Affilin®-219750 (SEQ ID NO: 15), Affilin®-219235 (SEQ ID NO: 17), Affilin®-220134 (SEQ ID NO: 18), Affilin®-220164 (SEQ ID NO: 19), and Affilin®-220257 (SEQ ID NO: 22) were tested. The reaction mixture contained 0.9 nM hFAP-Fc-His and 1 μM Affilin® protein. None of the Affilin® proteins tested reduced the enzymatic activity of hFAP-Fc-His.
[0123] Example 4. Expression and purification of FAP-binding proteins Genes of FAP-binding proteins were cloned into expression vectors using standard methods known to those skilled in the art, purified, and analyzed as described below. All FAP-specific proteins were expressed and highly purified by affinity chromatography and gel filtration. After affinity chromatography using a Strep-Tactin Superflow high capacity column, the eluted proteins were applied to size-exclusion chromatography (Superdex 75 HiLoad 16 / 600 or Sephacryl S200HR 16 / 600 column) using an AKTA xpress system (GE Healthcare). Elution with PBS containing 500 mM NaCl (pH 7.4) was performed in three column volumes. Positive fractions were pooled after SDS-PAGE analysis, and their protein concentrations were measured.
[0124] Further analysis included SDS-PAGE, RP-HPLC and SE-HPLC. Protein concentration was determined by absorbance measurement at 280 nm using the specific molar extinction coefficient. Reverse phase chromatography (RP-HPLC) was performed using an Ultimate 3000 HPLC system (Thermo Fisher Scientific) and a PLRP-S (5 μm, 300 Å) column (Agilent). Purity was found to be >78%. Analytical size exclusion chromatography (SE-HPLC) was performed using an Ultimate 3000 HPLC system (Thermo Fisher Scientific) and a Superdex75 increase 5 / 150 GL (Cytiva). No aggregation was detected.
[0125] Example 5. Analysis of FAP-binding proteins (surface plasmon resonance, SPR) Recombinant Protein A was immobilized on a High Capacity Amine sensor chip (Broker) after NHS / EDC activation to approximately 2000 RU using a Sierra SPR-32 system (Bruker). The chip was equilibrated with SPR running buffer (PBS 0.05%, Tween pH 7.3). An injection of ethanolamine after ligand immobilization was used to block unreacted NHS groups. Fc-tagged FAP and CD26 target molecules were injected at 60 nM, followed by the FAP-binding protein. On binding, the target analyte accumulated on the surface, increasing the refractive index. This change in refractive index was measured in real time and plotted as response or resonance units versus time. The FAP-binding protein was applied to the chip in serial dilutions at a flow rate of 30 μl / min. Association was allowed for 120 s and dissociation for 180 s. After each run, the chip surface was regenerated with 30 μl of regeneration buffer (10 mM glycine, pH 2.0) and equilibrated with running buffer. Binding studies were performed using a Sierra SPR-32 system (Bruker); data evaluation was performed via the Sierra Analyser software provided by the manufacturer using the Langmuir 1:1 model (RI = 0). The estimated dissociation constants (K D ) was normalized to immobilized protein and indexed. Table 1 shows the binding affinity of FAP-binding proteins to hFAP.
[0126] TIFF2024543910000002.tif109170
[0127] Affilin®-217990 (SEQ ID NO: 1), Affilin®-217862 (SEQ ID NO: 3), Affilin®-217832 (SEQ ID NO: 4), Affilin®-217863 (SEQ ID NO: 5), Affilin®-219235 (SEQ ID NO: 17), Affilin®-220164 (SEQ ID NO: 19), Affilin®-223078 (SEQ ID NO: 26), and Affilin®-223077 (SEQ ID NO: 27) bind (cross-specifically) to mouse FAP (mFAP) and human FAP (hFAP). The affinity of Affilin®-220164 for mFAP is 3.1 nM. The affinity of Affilin®-223078 for mFAP is 3 nM. The affinity of Affilin®-223077 for mFAP is 5 nM. The affinity of Affilin®-219235 for mFAP is 21.6 nM. The affinity of Affilin®-217990 for mFAP is 90 nM. Affilin®-217990 and Affilin®-217832 cross-specifically bind to cynomolgus monkey FAP (cFAP) and human FAP (hFAP), respectively. The FAP-specific Affilins® disclosed herein do not bind to hCD26 or mCD26.
[0128] Example 6. Competition of Binding Proteins for Epitopes Competitive binding of the two isolated Affilin® proteins to hFAP-Fc was examined as follows: the first Affilin®-protein was immobilized (approximately 200 RU) on a CM5 Biacore chip using NHS / EDC chemistry. 250 nM hFAP-Fc was injected with or without a 4-fold excess of a second Affilin® protein. The results are shown in Table 2. In Table 2, "competition" means that the binding of the first Affilin® is affected by the presence of the second Affilin® and vice versa. Affilin®-217993, Affilin®-217990, and Affilin®-217832 bind to the same or overlapping epitopes, i.e., to the same or overlapping surface-exposed amino acids.
[0129] TIFF2024543910000003.tif43170
[0130] Example 7. Functional characterization: FAP-binding proteins are stable at high temperatures The thermal stability of FAP-specific Affilin® proteins was determined by differential scanning fluorimetry (DSF) or circular dichroism (CD). For DSF measurements, each probe was transferred to a LightCycler 480 Multiwell Plate 96 (Roche) at a concentration of 0.25 μg / μL and SYPRO Orange dye was added at the appropriate dilution. A temperature gradient from 20°C to 90°C was programmed with a heating rate of 1°C / min (LightCycler480 RT-PCR-System, Roche). Fluorescence was measured continuously at an excitation wavelength of 465 nm and an emission wavelength of 580 nm. For CD measurements, samples were desalted in 20 mM NaH2PO4 (pH 7.0) using a HiTrap Desalting 5 ml column (Cytiva). FAP-binding proteins were diluted to a concentration of 0.2-0.4 μg / μl. A temperature gradient from 20° C. to 90° C. was performed with a heating rate of 0.5° C. / min (J-815, Jasco).
[0131] The midpoint of the transition for thermal denaturation (T m , melting point) were determined and are shown in Table 3.
[0132] TIFF2024543910000004.tif50170
[0133] Example 8. Functional characterization: specific binding to cell surface expressed hFAP (flow cytometry) Flow cytometry was used to analyze the interaction of FAP-binding proteins with cell surface exposed hFAP and mFAP. FAP-overexpressing human embryonic kidney cell line HEK293, CD26-overexpressing HEK293 cells, native FAP-expressing cell line Wi38 and empty vector control HEK293-pEntry cells were used. Anti-hFAP antibody (R&D Systems, MAB3715-100) at a concentration of 1 μg / ml combined with anti-mouse IgG-Alexa488 (Invitrogen, A10680) at a dilution of 1:1000 was used as a positive control for hFAP-expressing cells. Anti-mFAP antibody (R&D Systems, MAB9727) at a concentration of 1 μg / ml combined with anti-rat IgG-Alexa488 (Invitrogen, A11006) at a dilution of 1:1000 was used as a positive control for mFAP-expressing cells.
[0134] Cells were trypsinized, resuspended in medium containing FCS, washed, and stained in pre-chilled FACS blocking buffer (3% FCS / PBS). 6 Suspensions with a cell concentration of 100 cells / ml were prepared for cell staining and filled at 100 μl / well in 96-well plates (Greiner) in triplicate for each cell line.
[0135] Affilin® proteins were tested at concentrations of 1 μM, 100 nM, 10 nM, or 1 nM in FAP-expressing cells HEK293-hFAP, HEK293-mFAP, and Wi38 cells. To exclude non-specific binding, Affilin® proteins were also incubated at the same concentrations in CD26-expressing cells HEK293-hCD26 and HEK293-mCD26 and control cells HEK293-pEntry. An equivalent amount of wild-type ubiquitin (clone 139090) was used as a negative control. The supernatant was removed after 45 min, the cells were washed in blocking buffer, and 100 μl / well of rabbit anti-StrepTag antibody (GenScript; A00626) diluted 1:300 in FACS blocking buffer was added. After removal of the primary antibody, goat anti-rabbit IgG-Alexa Fluor 488 antibody (Invitrogen; A11008) was applied at a dilution of 1:1000. Flow cytometry measurements were performed on a Guava easyCyte 5HT device from Merck-Millipore with an excitation wavelength of 488 nm and an emission wavelength of 525 / 30 nm.
[0136] FACS experiments show that all Affilin® proteins disclosed herein bind to hFAP expressed on the cell surface of HEK293 cells. Unique strong binding (+++) was observed for Affilin®-217863, Affilin®-217862, Affilin®-217832, Affilin®-220164, Affilin®-223078, Affilin®-223077, Affilin®-223019, Affilin®-220257, and Affilin®-220198 (see Table 4).
[0137] Binding on the hFAP-expressing cell lines HEK293-hFAP and mFAP-expressing cell lines HEK293-mFAP could be confirmed for Affilin®-217990, Affilin®-220164, Affilin®-223078, Affilin®-223077, and Affilin®-219235. No binding to the control cells HEK293-hCD26 cells, HEK293-mCD26 cells or HEK293-pEntry was observed for the FAP-binding Affilin® proteins.
[0138] Furthermore, all Affilin® proteins disclosed herein demonstrated binding on native hFAP-expressing Wi38 cells. The anti-FAP antibody shows positive staining on all FAP-expressing cells. Wild-type ubiquitin showed no binding on FAP-expressing cells.
[0139] TIFF2024543910000005.tif116170
[0140] Example 9. Binding affinity to FAP in serum after long-term incubation (ELISA) 2.5 μg / ml hFAP-Fc was immobilized on high binding plates (Greiner, 781061) overnight at 4° C. A dilution series of Affilin® protein from 3 μM to 0.07 pM was incubated in 100% human serum or 100% mouse serum for 24 hours at 37° C. ELISA plates were washed three times with PBST (PBS + 0.1% Tween) and blocked with 3% BSA / 0.5% Tween / PBS for 1 h at room temperature. After 0 h or 24 h preincubation in the presence of serum, dilution series were incubated on ELISA plates for 30 min at room temperature (rt). Wells were washed with PBST and incubated with biotinylated anti-ubiquitin antibody (1:300) for 30 min at room temperature. Binding was visualized with Streptavidin-HRP (1:5.000). Affilin® proteins were stained with K after 24 h incubation in human or mouse serum. D No significant changes were observed in the K D The values are summarized in Table 5. ELISA analysis confirmed the high stability of the FAP-binding protein in serum.
[0141] TIFF2024543910000006.tif89170
[0142] Example 10. Binding affinity to FAP in serum after long-term incubation (cell binding assay - flow cytometry) A dilution series of Affilin®-217966 (SEQ ID NO:2), Affilin®-217862 (SEQ ID NO:3), and Affilin®-217863 (SEQ ID NO:5) from 30 μM to 2.1 pM was incubated in 100% human serum for 24 hours at 37° C. hFAP-expressing HEK293 cells were thawed, washed with medium containing FCS, followed by washing with FACS blocking buffer (PBS / 0.1% sodium azide / 3% FCS), and 100 μl was dispensed into a 96-well round-bottom plate at 1×10 6Cells were seeded at a density of 10000 cells / ml. A dilution series of Affilin protein was incubated with human serum for 24 hours and 0 hours (control) at 37°C. HEK293-hFAP cells were incubated with the dilution series for 45 minutes at 4°C. Cells were centrifuged and the supernatant was removed. Cells were washed with FACS blocking buffer and 100 μl / well of rabbit anti-Strep-Tag antibody (GenScript; A00626) diluted 1:300 in FACS blocking buffer was added. After removal of the primary antibody, goat anti-rabbit IgG Alexa Fluor 488 antibody (Invitrogen; A11008) was applied at a dilution of 1:1000 in FACS blocking buffer. Flow cytometry measurements were performed on a Guava easyCyte 5HT device from Merck-Millipore at an excitation wavelength of 488 nm and an emission wavelength of 525 / 30 nm. The results are shown in Figure 6. K of Affilin®-217863 D The determination shows no significant difference in binding to FAP even after 24 hours of serum incubation. Affilin®-217863 is stable in human serum. Similar results were obtained with Affilin®-217862 and Affilin®-217966.
Claims
1. A protein comprising an amino acid sequence having at least 90% identity to any one selected from the group consisting of SEQ ID NOs: 1-12, 15-27, and having a specific binding affinity for human fibroblast activation protein (hFAP) of less than 50 nM.
2. The protein of claim 1 which is a multimer.
3. The protein according to claims 1 to 2, which is a fusion protein.
4. The protein of claims 1 to 3, further comprising one or more linking sites for the attachment of chemical moieties.
5. The protein according to claims 1 to 4, which additionally comprises at least one diagnostically active moiety.
6. 6. The protein of claim 5, wherein the diagnostically active moiety is selected from a radionuclide, a fluorescent protein, a photosensitizer, a dye, an enzyme, a magnetic bead, a metal bead, a colloidal particle, an electron-dense reagent, biotin, digoxigenin, a hapten, CAR-T, or an exosome, or any combination thereof.
7. The protein according to claims 1 to 4, which additionally comprises at least one therapeutically active moiety.
8. 8. The protein of claim 7, wherein the therapeutically active moiety is selected from a monoclonal antibody or fragment thereof, a binding protein, a receptor or receptor domain, a receptor ligand, a radionuclide, a cytotoxic compound, a cytokine, a chemokine, an enzyme, CAR-T, or an exosome, or a derivative thereof, or any combination of the above.
9. The protein of claims 1 to 8, additionally comprising at least one pharmacokinetic modulating moiety.
10. A protein according to claims 1 to 9 for use in the diagnosis or treatment of a FAP-related disease.
11. A composition comprising a protein according to claims 1 to 9 for use in the diagnosis or treatment of an FAP-related disease.
12. A method for producing a protein according to claims 1 to 9, comprising the steps of a) culturing a host cell under suitable conditions to obtain said protein, and b) isolating the produced protein.
13. A method for detecting FAP constituting a sample using a protein according to claims 1-9, by contacting said sample with a protein according to claims 1-9.
Citation Information
Patent Citations
Generation of artificial binding proteins based on ubiquitin proteins
JP2008500953A
Novel EGFR-binding protein
JP2018505675A
Compositions and methods for cancer diagnosis and treatment
JP2018515066A
her2-binding protein based on a diubiquitin mutated protein
JP2018529310A
Modified multimeric ubiquitin proteins binding VEGF-a
WO2012172054A1
